



Title	Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes
Author(s)	Gui, H; Schriemer, D; Cheng, WC; Chauhan, RK; Antinolo, G; Berrios, C; Bleda, M; Brooks, AS; Brouwer, RWW; Burns, AJ; Cherny, SS; Dopazo, J; Eggen, BJL; Griseri, P; Jalloh, B; Le, TL; Lui, VCH; Luzon-Toro, B; Matera, I; Ngan, ESW; Pelet, A; Ruiz-Ferrer, M; Sham, PC; Shepherd, IT; So, MT; Sribudiani, Y; Tang, SM; van den Hout, MCGN; van der Linde, HC; van Ham, TJ; van IJcken, WFJ; Verheij, JBG; Amiel, J; Borrego, S; Ceccherini, I; Chakravarti, A; Lyonnet, S; Tam, PKH; Garcia-Barcelo, MM; Hofstra, RMW
Citation	Genome Biology, 2017, v. 18 n. 1, p. 48:1-13
Issued Date	2017
URL	http://hdl.handle.net/10722/241647
Rights	Genome Biology. Copyright © BioMed Central Ltd.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

RESEARCH

Open Access



Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes

Hongsheng Gui^{1,2†}, Duco Schriemer^{3†}, William W. Cheng^{1,4†}, Rajendra K. Chauhan⁴, Guillermo Antiñolo^{5,6}, Courtney Berrios⁷, Marta Bleda^{6,8}, Alice S. Brooks⁴, Rutger W. W. Brouwer⁹, Alan J. Burns^{4,10}, Stacey S. Cherny², Joaquin Dopazo^{5,6}, Bart J. L. Eggen³, Paola Griseri¹¹, Binta Jalloh¹², Thuy-Linh Le^{13,14}, Vincent C. H. Lui¹, Berta Luzón-Toro^{5,6}, Ivana Matera¹¹, Elly S. W. Ngan¹, Anna Pelet^{13,14}, Macarena Ruiz-Ferrer^{5,6}, Pak C. Sham², Iain T. Shepherd¹², Man-Ting So¹, Yunia Sribudiani^{4,15}, Clara S. M. Tang¹, Mirjam C. G. N. van den Hout⁹, Herma C. van der Linde⁴, Tjakko J. van Ham⁴, Wilfred F. J. van IJcken⁹, Joke B. G. M. Verheij¹⁶, Jeanne Amiel^{13,14}, Salud Borrego^{5,6}, Isabella Ceccherini¹¹, Aravinda Chakravarti⁷, Stanislas Lyonnet^{13,14}, Paul K. H. Tam¹, Maria-Mercè Garcia-Barceló^{1*} and Robert M. W. Hofstra^{4,10*}

Abstract

Background: Hirschsprung disease (HSCR), which is congenital obstruction of the bowel, results from a failure of enteric nervous system (ENS) progenitors to migrate, proliferate, differentiate, or survive within the distal intestine. Previous studies that have searched for genes underlying HSCR have focused on ENS-related pathways and genes not fitting the current knowledge have thus often been ignored. We identify and validate novel HSCR genes using whole exome sequencing (WES), burden tests, in silico prediction, unbiased in vivo analyses of the mutated genes in zebrafish, and expression analyses in zebrafish, mouse, and human.

Results: We performed de novo mutation (DNM) screening on 24 HSCR trios. We identify 28 DNMs in 21 different genes. Eight of the DNMs we identified occur in RET, the main HSCR gene, and the remaining 20 DNMs reside in genes not reported in the ENS. Knockdown of all 12 genes with missense or loss-of-function DNMs showed that the orthologs of four genes (DENND3, NCLN, NUP98, and TBATA) are indispensable for ENS development in zebrafish, and these results were confirmed by CRISPR knockout. These genes are also expressed in human and mouse gut and/or ENS progenitors. Importantly, the encoded proteins are linked to neuronal processes shared by the central nervous system and the ENS.

Conclusions: Our data open new fields of investigation into HSCR pathology and provide novel insights into the development of the ENS. Moreover, the study demonstrates that functional analyses of genes carrying DNMs are warranted to delineate the full genetic architecture of rare complex diseases.

Keywords: De novo mutations, Hirschsprung disease, Neural crest, ENS

* Correspondence: mmgarcia@hku.hk; r.hofstra@erasmusmc.nl

†Equal contributors

¹Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China

⁴Department of Clinical Genetics, Erasmus University Medical Center, PO Box 20403000CA Rotterdam, The Netherlands

Full list of author information is available at the end of the article



Background

Hirschsprung disease (HSCR) is the most common form of congenital obstruction of the bowel, with an incidence of ~1/5000 live births. The incidence varies significantly between ethnic groups, the highest being in Asia (2.8/10,000 live births) [1]. HSCR results from a failure of the neural crest (NC) cells, which give rise to the enteric nervous system (ENS), to migrate, proliferate, differentiate, or survive in the bowel wall, resulting in aganglionosis of the distal part of the gastrointestinal tract. This results in clinically severe and sometimes life-threatening bowel obstruction. As HSCR is a highly heritable disorder, genetic variation (mutations) in the genomes of these patients must largely explain disease development. So far more than 15 HSCR susceptibility genes, six linkage regions [1], and three associated loci [2, 3] have been found. The genes identified belong to a limited number of pathways relevant to the development of the ENS, among which the RET and the endothelin pathways are the most important. *RET* (encoding a tyrosine kinase) is the major gene with >80% of all known mutations. These have been mainly identified in ~50% of familial (mostly long-segment HSCR (L-HSCR), total colonic aganglionsis (TCA)) and up to 20% of sporadic (mostly short-segment HSCR (S-HSCR)) cases [4]. However, the identified genes and variants explain no more than 25% of the overall genetic risk of all HSCR cases [2, 3]. These findings indicate that the majority of the disease risk must be due to as yet unidentified rare or common variants in the known HSCR genes or, more likely, variants in yet unknown genes, acting alone or in combination.

The most popular approach to the analysis of whole exome sequencing (WES) data includes selecting genes that can be functionally linked to the pathways already known to be involved in the disease under study. Variants in genes totally unlinked to the known genes or pathways are largely neglected. This study aimed to determine the contribution of rare exonic, non-synonymous DNMs to HSCR without any a priori selection. Therefore, not only did we perform “standard” exome sequencing analyses, followed by burden tests and in silico prediction, but we also carried out an unbiased in vivo analysis of the mutated genes in a zebrafish model.

Results

Identification of de novo mutations

In total 24 HSCR trios (Additional file 1: Table S1) were included for WES analyses (Additional file 2: Figures S1 and S2). Sequencing metrics after the standard analytical pipeline (Additional file 2: Figure S2) are detailed in Additional file 3: Table S2 and Additional file 2: Figure S3. Specifically, the coverage of the targeted sequences per sample ranged from 18× to 74× (average 46×), and

the targeted exome was covered by at least ten sequence reads which ranged from 65 to 98% (average 88%). All these quality metrics or statistics showed data quality at exonic regions that were comparatively good for trios from different platforms or resources and justified our unbiased searching of de novo mutations in the following stages.

After validation, a total of 28 DNMs in 14 patients were identified (Table 1; Additional file 1: Table S1; Additional file 4: Table S3). The overall DNM rate per individual was 1.2 per exome per generation (Poisson distribution with $\lambda = 1.2$; Kolmogorov–Smirnov test, $p = 0.893$; Additional file 2: Figure S4), which is in accordance with the expected rate in the general population [5]. Several studies found that patients have a significantly higher fraction of loss of function (LOF) DNMs than healthy controls [6, 7]. In our HSCR patient cohort, the LOF DNM rate (8 out of 24 trios) is significantly higher than that of healthy trios (4 out of 54 trios; binomial test $p = 0.011$) or unaffected siblings of neuropsychiatric patients (54 out of 677 trios; binomial test $p = 0.001$) (Additional file 5: Table S4) [6, 8–11]; however, the enrichment of non-*RET* LOF DNMs (3 out of 24 trios) in our trios is not significant. These 28 DNMs were distributed among 21 genes. Eight DNMs were in *RET*, the major HSCR gene [12]. The observed *RET* DNM rate (0.33/trio) was significantly higher ($p < 2 \times 10^{-16}$) than that modeled in the general population (0.000133/trio) according to Samocha et al. [13].

One patient carried seven DNMs, two of which (*NCLN* and *DAB2IP*) were mosaic (Additional file 2: Figure S5). This is in line with a recent report stating that 6.5% of all DNMs are mosaic and occur post-zygotically [14]. Within the 24 patients, we looked for inherited rare damaging variants in the 21 genes carrying DNMs. Inherited damaging mutations were found in *RET*, *HMCN1*, *PLEKHG5*, *MAP4*, *SCUBE3*, and *KDM4A* (Additional file 6: Table S5). Neither de novo nor inherited copy number variants (CNVs) were detected.

Determining pathogenicity of the DNMs in silico

We mainly followed the guidelines from Veltman and Brunner [15] and MacArthur et al. [16] to determine the pathogenicity of the variants and genes found in this study. Firstly, to establish whether DNM genes carried significantly more rare variants in HSCR patients than in controls, we used WES data from the 20 eligible HSCR trio-probands, 28 additional HSCR patients, and 212 control individuals to calculate the variation burden per gene. Nine of the 21 genes (*RET*, *KDM4A*, *HMCN1*, *MAP4*, *NUP98*, *AFF3*, *COL6A3*, *CCR2*, and *CKAP2L*) were mutated in different sites in different HSCR patients (Additional file 7: Table S6). Meta-analysis of our gene burden tests showed that *RET* and *CKAP2L* were enriched for rare damaging variants in HSCR

Table 1 De novo mutations in Hirschsprung disease probands

Trio	Phenotype	Gene	De novo mutation	Type	MAF (dbSNP137/ESP6500/ExAC) ^a
1	L, F	RET	3splicing9 + 1	Splicing	N/N/N
		<i>RBM25</i>	c.474C > T;p.L158L	Synonymous	N/N/N
2	L, F	RET	c.2511_2519delCCCTGGACC;p.S837fs	Frameshift	N/N/N
		<i>COL6A3</i>	c.3327C > T;p.H1109H	Synonymous	4.2E-4 (rs114845780)/N/1.2E-4
3	L, F	RET	c.1818_1819insGGCAC;p.Y606fs	Frameshift	N/N/N
4	L, F	<i>DAB2IP</i>	c.2339C > T;p.T780M ^b	Missense	N/N/2.8E-3
		<i>ISG20L2</i>	c.961G > A;p.G321R	Missense	N/N/N
		<i>MED26</i>	c.675C > T;p.A225A	Synonymous	N/N/N
		<u><i>NCLN</i></u>	c.496C > T;p.Q166X ^b	Nonsense	N/N/N
		<u><i>NUP98</i></u>	c.5207A > G;p.N1736S	Missense	N/N/N
		<i>VEZF1</i>	c.584C > T;p.S195F	Missense	N/N/N
		<i>ZNF57</i>	c.570C > T;p.D190D	Synonymous	N/N/N
5	L, F	RET	c.1761delG :p.G588fs	Frameshift	N/N/N
		<i>SCUBE3</i>	c.1493A > T;p.N498I	Missense	N/N/N
6	L, M	<i>AFF3</i>	c.1975G > C;p.V659L	Missense	N/N/N
		<i>PLEKHG5</i>	c.2628G > T;p.T876T	Synonymous	N/N/9.1E-6
7	L, M	<i>KDM4A</i>	c.26A > G;p.N9S	Missense	N/N/N
8	L, M	<i>MAP4</i>	c.3351C > T;p.G1117G	Synonymous	N/N/9.2E-6
9	L, F	RET	c.1858 T > C;p.C620R	Missense	0 (rs77316810)/N/N
10	TCA, M	<i>CKAP2L</i>	c.555_556delAA;p.E186fs	Frameshift	N/2E-5/2.5E-5
11	L, F	RET	c.409 T > G;p.C137G	Missense	N/N/N
		<i>HMCN1</i>	c.10366G > A;p.A3456T	Missense	N/N/N
		<i>TUBG1</i>	c.699 T > C;p.S233S	Synonymous	N/N/8.2E-6
12	L, F	<i>CCR2</i>	c.848 T > A;p.L283Q	Missense	N/N/N
		<u><i>DENND3</i></u>	c.1921delT;p.K640fs	Frameshift	N/N/N
13	L, F	RET	c.1710C > A;p.C570X	Nonsense	N/N/N
14	L, F	RET	c.526_528delGCA;p.R175del	Non-frameshift	N/N/N
		<u><i>TBATA</i></u>	c.157C > T;p.R53C	Missense	N/N/4.1E-5

Genes in bold indicate patients carrying de novo *RET* mutations. Underlines genes are genes giving a HSCR-like phenotype in zebrafish.

F female, L long-segment HSCR, M male, TCA total colonic aganglionsis

^aMinor allele frequency (MAF) in dbSNP137, ESP database or ExAC database, with "N" standing for no data available.

^bMosaic mutation

(uncorrected $p < 0.05$; Table 2; Additional file 7: Table S6), though our sample size is underpowered for genome-wide statistical tests (Additional file 2: Figure S6). However, crosschecking these 21 genes in another in-parallel HSCR WES (190 cases, 740 controls) revealed that only *RET* was significantly overrepresented with deleterious variants ($p < 0.001$; A. Chakravarti, manuscript in preparation).

Besides the eight LOF mutations, six out of twelve missense mutations were consistently predicted to be deleterious (Additional file 8: Table S7). As for the seven synonymous DNMs, we found no in silico evidence indicating that those changes interfered with splicing and/or RNA structure (Additional file 8: Table S7). After checking those genes with DNMs against the ATGU's gene look-up server [13] and the Exome Aggregation

Consortium (ExAC) Browser [17], in total 11 genes (Table 2) were identified as evolutionarily constrained where variants are more likely to be deleterious [13]. Next we checked whether the genes with DNMs were functionally related to each other and/or to the signaling networks known to govern ENS development. Although no direct in silico interactions were found among the 21 genes, *ISG20L2* and *MAP4* showed more indirect interactions with other genes with DNMs than that expected by chance ($p = 0.0063$ and $p = 0.0167$, respectively). A list of 116 ENS-related genes (Additional file 9: Table S8) was used to study the functional link between DNM genes (other than *RET*) and ENS. Only a single interaction was identified (*COL6A3* interacts with *ITGB1*). Ingenuity Pathway Analysis identified additional direct

Table 2 Genes carrying de novo mutations

Gene	Number of amino acids	Co-occurrence with <i>RET</i> DNM	Burden test meta-analyses (uncorrected <i>p</i> value)	Gene constraint prediction (AGTU; ExAC) ^a	Zebrafish ENS phenotype	Gut expression (human; mouse; zebrafish) ^b
<i>PLEKHG5</i>	1062	No	0.3997	No; No	NT	Yes; Yes; ND
<i>KDM4A</i>	1064	No	0.1190	No; Yes	No	Yes; Yes; ND
<i>ISG20L2</i>	353	No	0.4949	No; No	No	Yes; Yes; ND
<i>HMCN1</i>	5635	Yes	0.9789	No; No	No	Yes; Yes; ND
<i>AFF3</i>	1226	No	0.4745	No; Yes	No	Yes; Yes; ND
<i>CKAP2L</i>	745	No	0.0178	No; No	No	Yes; Yes; ND
<i>COL6A3</i>	3177	Yes	0.6398	No; No	NT	Yes; Yes; ND
<i>CCR2</i>	374	No	0.4745	No; No	No	Yes; Yes; ND
<i>MAP4</i>	1152	No	0.4851	No; Yes	NT	Yes; No; ND
<i>SCUBE3</i>	993	Yes	0.7133	Yes; Yes	No	Yes; Yes; ND
<i>DENND3</i>	1198	No	0.5977	No; No	Yes	Yes; Yes; Yes
<i>DAB2IP</i>	1189	No	0.9819	No; Yes	No	Yes; Yes; ND
<i>RET</i>	1114	-	0.0078	No; Yes	Yes	Yes; Yes; ND
<i>TBATA</i>	351	Yes	0.8028	NA; No	Yes	No; Yes; Yes
<i>NUP98</i>	1817	No	0.7243	No; Yes	Yes	Yes; Yes; Yes
<i>RBM25</i>	843	Yes	0.0846	Yes; Yes	NT	Yes; Yes; ND
<i>TUBG1</i>	451	Yes	1.0000	Yes; Yes	NT	Yes; Yes; ND
<i>VEZF1</i>	521	No	0.6717	No; Yes	No	Yes; Yes; ND
<i>ZNF57</i>	555	No	0.3808	No; No	NT	Yes; No; ND
<i>NCLN</i>	563	No	0.4949	No; No	Yes	Yes; Yes; Yes
<i>MED26</i>	600	No	1.0000	No; Yes	NT	Yes; Yes; ND

^aGenes evolutionarily constrained as per AGTU's server and ExAC database: "No" for not constrained, "Yes" for constrained, "NA" for not available.

^bData from in-house human induced pluripotent stem cell-derived neural crest, mouse expression data, and RT-PCR and in situ hybridization in zebrafish; ND not done.


NT not tested (gene carries synonymous mutation and/or has no ortholog in zebrafish)

and indirect relationships with ENS-related genes for *MAP4*, *COL6A3*, *RBM25*, and *TUBG1* (Additional file 2: Figure S7). All genes carrying DNMs were either expressed in human induced pluripotent stem cell (iPSC)-derived enteric neuron precursors or in primary murine enteric neuron precursors (Table 2).

Determining pathogenicity of the DNMs in vivo

Thirteen genes had a LOF or missense mutation but were not obvious candidates for HSCR as there was no previous report linking these genes to ENS development or HSCR pathogenesis. We used the zebrafish model system to further investigate the function of these genes in ENS development. We used the model as previous studies have shown that morpholino-mediated knockdown of orthologs of known HSCR genes did result in an HSCR-like phenotype in zebrafish [3, 18]. Except *CCR2*, all 13 genes with nonsynonymous DNMs have zebrafish orthologs. Splice-blocking morpholinos (SBMOs) against the 12 genes were injected into *Tg(-8.3phox2b:-Kaede)* transgenic zebrafish [19] embryos that express the fluorescent protein Kaede in enteric neuron precursors and

differentiated enteric neurons, while its effect on gene transcription was confirmed by quantitative PCR (qPCR)/RT-PCR expression pattern. Initially, knockdown of five orthologs (*ckap2l*, *dennd3a* and *b*, *ncl1*, *nup98*, and *tbata*) resulted in a HSCR-like phenotype as enteric neurons were absent in the distal intestine of embryos 5 days post-fertilization (dpf) (Fig. 1a–e), while embryos injected with 5-nucleotide mismatch control morpholinos had normal ENS development with enteric neurons present along the entire length of the intestine (Fig. 1f–j). It was reported that morpholinos might induce target-independent apoptosis through p53 activation that leads to an unspecific off-target phenotype [20]. To confirm the HSCR-like phenotype observed in the morphants resulted from target-specific knockdown, we co-injected the SBMOs with p53 morpholino, which would inhibit p53 activity and thereby block the unspecific apoptosis. As a result, the phenotype could not be reproduced by *ckap2l* SBMO and p53 morpholino co-injection (Fig. 1k), suggesting the phenotype observed initially was an off-target effect. On the contrary, co-injection of p53 morpholino with *dennd3a* and *b*, *ncl1*, *nup98*, or *tbata* SBMOs resulted in the same phenotype



(Fig. 1l–o), indicating the phenotype was not caused by unspecific apoptosis. qPCR analysis showed that the expression of *dennd3a*, *dennd3b*, *nup98*, and *tbata* was markedly reduced in the SBMO-injected embryos (Additional file 2: Figure S8). Intriguingly, there was no significant reduction in *ncl1* expression in the *ncl1* SBMO-injected embryos. Therefore, we further investigated it by performing RT-PCR on individual embryos and found that there was a large variation in *ncl1* expression between embryos injected with the SBMO, with some of them showing a clear reduction in *ncl1* transcript level (Additional file 2: Figure S9). Of the zebrafish orthologs that did not show a specific HSCR-like phenotype after SBMO injection, all demonstrated significant reductions in expression except for *aff3*, *scube3*, and *vezfla* (Additional file 2: Figure S8). We verified the results by repeating the knockdown experiment with a second, non-overlapping translation-blocking morpholino (TBMO) against *dennd3a* and *b*, *ncl1*, *nup98*, or *tbata* and the HSCR-like phenotype was reproduced (data not shown). Overall, from the morpholino knockdown experiment we identified 4 out of 12 candidate genes that were important for ENS development and caused a HSCR-like phenotype when their functions were disrupted.

With the recent improvement in the CRISPR knockout protocol in zebrafish, which enabled phenotype analysis in guide-RNA (gRNA)-injected F0 larvae [21], we

decided to carry out CRISPR knockout of *ckap2l*, *dennd3a* and *b*, *ncl1*, *nup98*, and *tbata* to further strengthen our data obtained from morpholino knockdown. We first tested the protocol by injecting *ret* gRNA and observed loss of enteric neuron phenotype in 5-dpf F0 larvae (data not shown). *ckap2l* gRNA did not cause a HSCR-like phenotype (Fig. 1p), reaffirming the interpretation that the initial observation in morpholino knockdown was an off-target effect. CRISPR knockout of *dennd3a* and *b*, *ncl1*, *nup98*, and *tbata* all resulted in the loss of enteric neurons in 5-dpf larvae (Fig. 1q–t). The presence of indel mutation at the target site was confirmed by T7E1 assay (Additional file 2: Figure S10). Therefore, we concluded that *DENND3*, *NCLN*, *NUP98*, and *TBATA* orthologs' loss of function disrupted ENS development and caused a HSCR-like phenotype in vivo.

Temporal analysis using RT-PCR revealed zebrafish orthologs (*dennd3a*, *dennd3b*, *ncl1*, and *nup98*) for *DENND3*, *NCLN*, and *NUP98* were maternally and zygotically expressed from 0–120 hpf while the *TBATA* ortholog (*tbata*) is only zygotically expressed from 24–120 hpf (Additional file 2: Figure S11). Whole mount in situ hybridization (WISH) analysis showed that the orthologs for all four genes were expressed in distinct spatial locations specifically in the intestine and the anterior central nervous system (CNS) from 24–96 hpf,

suggesting a role not only in ENS development but also in the CNS (Fig. 2).

Mutation profile of HSCR patients

Out of the 14 patients with DNM, eight carried mutations in *RET* and six in genes other than *RET*. Interestingly, one of the patients with *RET* DNM also harbored DNM in genes that recapitulate HSCR in zebrafish (*TBATA*), suggesting that, in humans, mutations in more than one gene might be necessary for the phenotype to develop. Among the six patients with no *RET* DNM, two (*HSCR4* and *HSCR12*; Table 1) harbored functionally supported DNMs. Overall, we observed 33% (8 out of 24) diagnostic rate for *RET* mutations in all our patients, but 62.5% (5 out of 8) if considering only those non-prescreened trio probands. This is consistent with previous report on *RET* contribution to L-HSCR [4].


Besides, since both rare and common variants jointly contribute to HSCR, we examined the genetic profile (Additional file 6: Table S5) of our patients to assess the genetic background on which the DNMs reside. Each patient was investigated for the presence/absence of the common HSCR-associated *RET* allele (rs2435357T) [22] as well as for the presence of rare variants (inherited from unaffected parents) in a set of 116 ENS-related pre-selected genes (Additional file 4: Tables S3; Additional file 9: Table S8). We did observe common *RET* risk alleles and rare damaging mutations in ENS candidate genes in all patients (Additional file 6: Table S5), regardless of their DNM status. Whether common or rare *RET* risk alleles and/or rare mutations in ENS genes in the background contribute to the phenotype would need further research.

Discussion

Over the past years a large number of papers have been published on de novo mutation screening in human

diseases. This has resulted in the identification of many new disease-associated genes. Genes are considered as true disease causing when there is a significant excess of de novo mutations among unlinked patients. This works well for diseases that are relatively homogeneous or for which many patients can be investigated. For the more heterogeneous rare diseases for which only small cohorts are available this poses a problem. Often possible disease causing genes are found in a single patient. How to decide whether this finding is of importance? Expression of the gene in the relevant tissues can be considered as additional evidence, as is network analysis. However, making strong statements for private disease genes is, and will be, extremely difficult. It also results in a bias towards genes in the known disease-causing gene networks. Genes not fitting the current knowledge are often discarded as uninteresting. In the current study we wanted to take this all one step further.

Therefore, to assess if the mutated genes play a role in ENS development, we performed two rounds of functional analyses. We opted for an in vivo approach using the zebrafish model system. We knocked down the expression of zebrafish orthologs of 12 of the 13 genes in which loss-of-function or missense DNMs had been identified. Nine genes were successfully knocked down and four of them resulted in loss of neurons in the distal gut. It was noted that in some morphants the proportion of larvae displaying a HSCR-like phenotype was comparatively low. Although in most cases we could improve the efficacy by increasing the amount of morpholino injected, this also led to a higher death rate and more dysmorphic larvae caused by the general toxicity of the morpholino. Therefore, we chose the dose that caused the minimum death rate and dysmorphic rate with slightly lower, but still valid, efficacy. It should also be noted that in some of the morphants the gut



development appeared to be affected. Perhaps it was not surprising as from the in situ hybridization results some of these genes seemed to be expressed in the surrounding intestinal tissues as well. Therefore, when hypothesizing the function of these genes in ENS development, in addition to the intrinsic effect on enteric neural crest cells, one should not rule out the possibility of the extrinsic influence via the intestinal tissues. Noteworthy, the SBMOs targeting three of the orthologs (*aff3*, *scube3*, and *vezf1a*) did not knockdown the target transcripts as expected, highlighting the limitation of morpholinos [23]. To strength our morpholino data we opted for CRISPR knockout, which allowed phenotype analysis in F0 larvae. The HSCR-like phenotype was reproduced in the CRISPR knockout of *dennd3a* and *b*, *ncl1*, *nup98*, and *tbata*. Although the presence of indel mutation was confirmed by T7E1 assay in all larvae injected with gRNA, the number of larvae displaying the phenotype was relatively low. We suspected this was mainly due to the varying CRISPR efficiency (number of indels present in the target gene over the total number of the target gene copy in a larva) between larvae.

For those four mutations from the newly validated genes (*DENND3*, *NCLN*, *NUP98*, and *TBATA*), two of them (*NCLN:Q166** and *DENND3:K640fs*) are loss-of-function mutations that disrupt gene translation; the other two (*NUP98: N1662S* and *TBATA:R53C*) are predicted as highly deleterious by Polyphen2 and a logistic regression model that combine different predicted scores [24]. This in silico evidence (Table S8) strongly supports the potential impact of the mutations on their genes [15]; hence, we do not report any functional assay to validate them in this study.

The finding of these four genes recapitulating HSCR in zebrafish clearly demonstrates that genes that would have never been followed up based on the usual gene selection criteria should not be ignored. Using bioinformatics prediction and statistics, we would have focused on *RET* and *CKAP2L* as they were the only genes significantly enriched for rare variants in patients.

We wondered whether any of these four genes could be linked to the ENS or whether they play relevant roles in neuronal development or NC-derived cell types in general. In fact, by studying these genes in more depth we noticed that all four, despite a lack of obvious connection to the known ENS pathways, are involved in the development of the CNS or the NC, making these not as random as they might first appear.

DENN/MADD domain containing 3 (*DENND3*) is a guanine nucleotide exchange factor (GEF) that is involved in intracellular trafficking by activation of the small GTPase *RAB12* [25]. In zebrafish, *Rab12* and other Rab GTPases are highly expressed by pre-migratory NC cells and their expression is dysregulated in *Ovo1*

morphant zebrafish that display altered migration of NC cells [26]. Independently of *RAB12*, *DENND3* also regulates Akt activity, which is involved in the proliferation and survival of enteric NC cells [25, 27].


Nicalin (*NCLN*) is a key component of a protein complex that antagonizes Nodal signaling [28], which in vertebrates is involved in induction of the mesoderm and endoderm [29]. In contrast, inhibition of Nodal signaling is required for the specification of human embryonic stem cells into neuroectoderm, including the NC [30, 31]. The antagonizing function of Nicalin on Nodal signaling is therefore consistent with the NC specification required for ENS development.

NUP98 encodes a precursor protein that is autoproteolytically cleaved to produce two proteins: *NUP98* from the N-terminus and *NUP96* from the C-terminus [32]. A missense DNM was identified in the last exon of the *NUP98* gene and therefore affects the *NUP96* protein. As in humans, zebrafish *Nup96* is produced by cleavage of the *Nup98* precursor protein. Since morpholinos act on the mRNA level, both *nup98* and *nup96* were targeted in our zebrafish experiments. It is therefore unclear whether the observed aganglionosis is caused by loss of *Nup98* or *Nup96*. *NUP96* is one of approximately 30 proteins in the nuclear pore complex (NPC) [33] and its expression level regulates the rate of proliferation [34]. Two other members of the NPC (*Nup133* and *Nup210*) are involved in neural differentiation in mice [35, 36]. Moreover, *NUP96* interacts with *NUP98* and *NUP98* is involved in transcriptional regulation of the HSCR genes *SEMA3A*, *DSCAM*, *NRG1*, and the *NRG1* receptor *ERBB4* in human neural progenitor cells [37]. Therefore, it is likely that loss of both *NUP* proteins (*NUP96* or *NUP98*) could contribute to HSCR development.

The mouse ortholog of *TBATA* (Thymus, brain and testes associated) is called *Spatial* and is highly expressed during differentiation of several tissues [38]. These include the cerebellum, hippocampus, and Purkinje cells in the brain, where *TBATA/Spatial* is expressed in early differentiating neurons [39]. In mouse hippocampal neurons, *TBATA/Spatial* is required for neurite outgrowth and dendrite patterning [40].

The four newly identified HSCR candidate genes seem to play a role in neuronal development and could potentially be involved in HSCR (Fig. 3). This also suggests a clear link between CNS and ENS development. This does not come as a total surprise, as several known HSCR genes (e.g., *KBP*, *SOX10*, *NRG1*, *IKBKAP*, *ZEB2*, *PHOX2B*) are involved in both CNS and ENS pathologies [2, 41–43] and the fact that HSCR is strongly associated with Down syndrome.

Besides the fact that several HSCR/neuromuscular genes are known to be associated with CNS defects, the opposite is also described. Many neurological and



psychiatric disorders are associated with constipation, and sometimes defects in the ENS are reported [44]. For instance, it has recently been described that mutations in *CDH8* result in a specific subtype of autism in combination with gastrointestinal problems. A *cdh8*^{-/-} zebrafish recapitulates the human phenotype, including increased head size, impairment of gastrointestinal motility, and reduction in post-mitotic enteric neurons [45]. Besides, searching “CNS” and “autism” in Phenolyzer (<http://phenolyzer.wglab.org/>) returns two ENS genes, *APP* [46] and *MECP2* [47].

Given the fact that HSCR occurs together with neurological disorders more often than expected, it is not surprising that dysfunction of these newly identified neurological-related genes results in dysregulation of the NC-derived cells that form the ENS, and hence in HSCR. These data are further corroborated by the expression patterns we observed for the orthologs of these four genes in zebrafish embryos (Fig. 2), with all four being expressed in both brain and gut.

Using zebrafish as a model we have experimentally shown that some of the genes with de novo mutations appear to be functionally or biologically linked with the ENS. As the effect of de novo variants on the phenotype may depend on the genetic background, it is tempting to speculate that those genes that failed to reproduce the HSCR phenotype in zebrafish could, in fact, contribute to the disease in humans.

While statistical evidence of involvement in HSCR has only been attained for RET, the functional studies presented here support the possible contribution of DENND3, NCLN, NUP98, and TBATA to the disorder. Finding a role for these genes in ENS development will open new research avenues and enhance our knowledge about ENS development and HSCR disease mechanisms. Until now, we believed that the number of cellular processes involved in the development of HSCR was limited. Clearly this idea needs to be revisited as the novel genes we identified are not directly linked to any of the currently known HSCR gene networks.

Conclusions

Our data open new fields of investigation into HSCR pathology and provide insight into the development of both the ENS and CNS. Moreover, as a lesson for all those who work on rare heterogeneous diseases, the study demonstrates that functional analyses of genes carrying DNMs is warranted to delineate the full genetic architecture of rare complex diseases.

Methods

Study samples

Trios

A total of 24 trios (affected child and unaffected parents) without family history of HSCR recruited in five different centers were included for whole exome sequencing

(WES). The patients were all non-syndromic. Five trios were of Chinese origin whereas 19 were of Caucasian ancestry. We prioritized the most/more severe and rarer HSCR cases for this study, namely female patients with long segment or total colonic aganglionosis. Sixteen out of the 24 patients had previously tested negative for *RET* damaging variants by traditional technologies. Characteristics of the patients are presented in Additional file 1: Table S1. Informed consent was obtained from all participants.

Case-control

WES data from 28 additional sporadic HSCR patients without sub-phenotype limitation (singletons) and 212 controls were used to check gene recurrence and assess the gene burden for rare variants (Additional file 1: Table S1).

Data generation

Whole exome sequencing

DNA samples were sequenced in four centers. The exome-capture kit and sequence platforms used per center are detailed in Table S2. Appropriate mapping tools (Burrows–Wheeler aligner (BWA) for Illumina data and Bfast for Solid data) were used to align sequence reads to the human reference genome (build 19) [48]. Sequence quality was re-evaluated using the FastQC toolbox, Picard's metric summary, and the Genome Analysis Toolkit (GATK) Depth-of-Coverage module. After initial quality control (QC) all eligible sequences were pre-processed for local indel realignment, PCR duplicate removal, and base quality recalibration [49].

Genome-wide SNP array

To determine copy number variants (CNVs) and regions of homozygosity, DNA was hybridized to the Human-Cyto SNP12 BeadChip (Illumina, San Diego, CA, USA) according to standard protocols.

Variant calling and prioritization

Aligned reads from all sequenced samples were pre-processed according to standard guidelines [49]. Variant calling was done independently for Illumina reads or Solid reads using the GATK unified Genotyper 2.0 [50]. To avoid mismatched regions across different capture kits, calling was performed whole genome-wide without limiting to any capture array. A special setting (allow potentially miscoded quality scores) was used to make color-spaced solid reads compatible to the program (Broad institute). Raw variants (including single nucleotide variants and short insertions/deletions) with individual genotypes and their affiliated quality scores were stored in a standard VCF format after calling. Quality assessment (QA) and QC were then adopted on a few sets

of variants (raw variants, exonic variants, rare variants) to generate a confident variant set for downstream prioritization (Additional file 1: Supplementary methods). A clean variant set at exonic regions was produced after variant-level and genotype-level QC. Rare coding sequence variants were then prioritized by filtering out those variants with minor allele frequency >0.01 in any of these public databases (dbSNP137, 1000 Human Genome project, and NHLBI Exome Sequencing project). An automatic pipeline integrating GATK [49], KGGSeq [51], Annovar [52], and Plink [53] was used to generate the final set of qualified variants (Additional file 2: Figure S1).

Identification of DNMs

WES DNM detection

Rare, exonic variants present in the probands but absent in both parents were considered DNMs. To select putative DNMs (or de novo variations) the following criteria were used: 1) minimal coverage of five in patients and parents; 2) a minimal genotype quality score of 10 for both patients and parents; 3) at least 10% of the reads showed the alternative allele in patients; and 4) not more than 10% of the reads showed the alternative allele in parents. Subsequently all remaining DNM variants were manually inspected using the Integrated Genome Viewer (IGV) and classified into five different confidence ranks according to their base-calling quality and strand bias. The first two ranks of DNM candidates were selected for validation by Sanger sequencing; while the other three classes of candidates were re-evaluated by a model trained from variants submitted for Sanger sequencing (Additional file 2: Supplementary methods).

RET gene inspection

To guarantee that no de novo mutations had been missed in the major HSCR gene, the depth of coverage of each of the 21 exons of *RET* was manually inspected for each patient. All exons with a coverage <10 were Sanger sequenced. Mutation Detector software (Thermo Fisher Scientific) was used to identify rare coding sequencing mutations from raw Sanger sequences; any mutation found in a trio proband was further checked in his/her parents. Besides rare mutations, bi-allelic genotypes for the common risk single nucleotide polymorphisms (IVS1 + 9494, rs2435357T) were extracted from local databases or newly genotyped.

CNV detection

The Nexus® software program (Biodiscovery, El Segundo, CA, USA) was used to normalize and analyze the SNP array data as mentioned above. Loss is defined as the loss of a minimum of five probes in a 150-kb region, with a minimum log R ratio of -0.2. Gain is defined as

the gain of a minimum of seven probes in 200-kb region, with a minimum log R ratio of 0.15. The minimum length of regions of homozygosity analysed was 2 Mb. The identified CNVs were reviewed for pathogenicity using the UCSC genome browser (<http://genome.ucsc.edu/>), the DGV database (<http://dgv.tcag.ca/dgv/app/home>), the Decipher database (<https://decipher.sanger.ac.uk/>), and our in-house local reference database that consists of 250 healthy controls and 250 individuals of the general population.

Statistical tests

De novo mutation rate

All proven DNMs were classified into loss-of-function (nonsense single nucleotide variants (SNVs), frame-shift indels and splicing sites), missense SNVs, in-frame indels, and synonymous SNVs. The counts of DNM per trio were fitted to a Poisson distribution with lambda as observed mean. De novo mutation rates were calculated for these DNM subtypes and compared to 677 published healthy trios and neurodevelopmental disease trios using a binomial test [6–8, 10, 11, 54]. Given the per-gene mutation rate in Samocha et al. [13], statistical over-representation of mutations in all 24 genes were calculated using Fisher's exact test.

Gene-wide burden analysis

Genes with DNMs were further scrutinized for the presence of inherited rare damaging variants in the trios as well as in HSCR singletons for whom WES data were available. A detailed analytical protocol was shared before running the association in each center. Briefly, genotypes of rare damaging variants (as previously defined) in genes carrying one or more de novo mutations were extracted from raw sequencing reads. The CMC test in the Rvtest package was used to collapse multiple variants into the same gene (boundary defined using hg19 refgene) and compare overall burden between cases and local matched controls [55]. *P* values were estimated by asymptotic chi-square distribution. The gene-wise *p* value, burden direction, and variant count per gene were exported. Ultimately, the sample size weighted Z-score method was used to conduct meta-analysis on gene-wise summary statistics from three centers using the same protocol.

Bioinformatics analysis

Variant-level implication

The impact of each DNM to its carrying gene was predicted using several bioinformatics tools or databases. The conservation of missense SNVs was predicted using GERP and PhyloP across 29 different species. The deleteriousness of missense or nonsense SNVs were determined by a logit model incorporating five prediction

programs (Polyphen2, Sift, MutationTaster, PhyloP, and likelihood ratio) [24]. Human Splicing finder was used to predict whether DNMs causing synonymous change or locating at splicing sites (exon ± 2 bp) created or disrupted splice sites [56]. To assess if synonymous DNMs had any effect on the transcripts, we used RNAmute [57]. Finally, ClinVar and PubMed were searched for the same or similar mutations in the same gene that present in healthy controls or other disease patients.

Gene-level implication

Evidence of gene-level implication was collected from two aspects. First, those 24 genes carrying DNMs were searched against databases (the ATGU's server (<https://github.com/michaelchess/gene-lookup>) and ExAC browser (<http://exac.broadinstitute.org/>)) for recurrence and constrained scores [13, 17]. Second, ENS candidate genes/gene sets were curated (Additional file 1: Supplementary methods) [58–60] and then linked to newly identified genes using pathway or protein–protein interaction network information. Disease Association Protein–Protein Link Evaluator (DAPPLE) was used to test whether the genes carrying DNMs in our study are functionally connected to each other. The significance of observed pathway enrichment and network connectivity was evaluated empirically using randomly selected genes from among genes of the same genomic size as the identified DNM genes. InWeb and Ingenuity Pathway Analysis were used to detect direct and indirect protein interactions between ENS-related genes and genes with DNMs.

Gene expression in the ENS

In order to test the involvement of the newly identified genes in ENS development, in-house expression data were shared from other parallel projects in the Hong Kong and Rotterdam centers. The first expression dataset was from RNA sequencing on an iPSC-induced enteric neural crest cell (ENCC) for a HSCR patient; the second and third expression datasets were from microarray chips on embryonic mouse gut and ENCC.

Zebrafish

Tg(-8.3phox2b:Kaede) transgenic zebrafish (*Danio rerio*) embryos were obtained from natural spawning. Maintenance of zebrafish and culture of embryos were carried out as described previously [61]. Embryos were staged by hours (hpf) or days (dpf) post-fertilization at 28.5 °C.

Gene knockdown by antisense morpholinos

Antisense morpholinos (MOs; Gene Tools LLC) targeting the zebrafish orthologs of the candidate genes, by blocking either translation or splicing, were microinjected to one- to four-cell stage *Tg(-8.3phox2b:Kaede)* transgenic zebrafish embryos as previously described

[19]. For candidate genes that are duplicated in the zebrafish genome, morpholinos targeting all paralogs were co-injected. A standard control MO and 5-nucleotide mismatch control MOs for *ckap2l*, *dennd3a*, *dennd3b*, *ncl1*, *nup98*, and *tbata* were used as negative control. Embryos were raised to 5 dpf, analyzed, and imaged under a stereo fluorescence microscope (Leica MZ16FA and DFC300FX). An HSCR-like phenotype was defined as the absence of enteric neurons in the distal intestine in 5-dpf embryos. Sequences and dosages of all MOs used are included in Additional file 10: Table S9.

Gene knockout by CRISPR/Cas9

The design and synthesis of gRNA were carried out as described [62]. Briefly, CRISPRscan (<http://www.crisprscan.org/>) was used to design gRNA sequences against *ckap2l*, *dennd3a*, *dennd3b*, *ncl1*, *nup98*, and *tbata*. Designs with high predicted efficiency and low predicted off-target effects were chosen. DNA templates for gRNA synthesis were generated by PCR fill-up reaction [62] and the gRNAs were synthesized using a MEGAscript™ T7 Transcription Kit (Invitrogen). gRNA (150 pg) was co-injected with recombinant 667 pg Cas9 protein to one-cell stage *Tg(phox2b:kaede)* embryos. For *dennd3a* and *dennd3b* knockout 75 pg of each gRNA was co-injected with Cas9. The injected larvae and un-injected control were cultured to 5 dpf for phenotype checking and imaging. Each larva was collected separately for genomic DNA extraction and T7E1 assay to confirm the presence of indel mutation as described previously [21]. In brief, the genomic region flanking the gRNA target site was amplified by PCR. The PCR product was denatured and slowly re-annealed to allow the formation of a heteroduplex. The re-annealed PCR product was digested with T7 endonuclease I (New England Biolab) at 37 °C for 45 min and then resolved by 2% agarose gel electrophoresis. The sequences of gRNAs and primers are listed in Additional file 11: Table S10.

Expression analysis

To confirm the target genes were successfully knocked down, total RNA was extracted from 1-dpf embryos ($n = 50$) injected with the splice blocking MO using RNA Bee (Amsbio) and cDNA were reverse transcribed using a iScript cDNA Synthesis Kit (Bio-rad). qPCRs were performed using a KAPA Sybr® Fast qPCR Kit (KAPA Biosystems; see Additional file 12: Table S11 for primer details) and the expression of the target gene was normalized by the mean expression of two housekeeping genes (*elfa* and *actb*). The relative expression of the target gene in the splice blocking MO-injected embryos to the control MO-injected embryos was determined by the Livak method [63].

To determine the temporal expression of the zebrafish ortholog, RT-PCR was performed at various time points with primers used to amplify a segment of the open reading frame of each gene. To determine the spatial expression patterns of *dennd3a*, *dennd3b*, *ncl1*, *nup98*, and *tbata*, antisense digoxigenin-labeled probes for both genes were generated and whole-mount in situ hybridization was performed as described by Thisse et al. [64].

Additional files

Additional file 1: Table S1. Information on samples included in the study. (XLSX 10 kb)

Additional file 2: Supplementary methods and Figures S1–S11. (PDF 4258 kb)

Additional file 3: Table S2. Quality metrics for sequencing reads and variants from different cohorts. (XLSX 9 kb)

Additional file 4: Table S3. Statistical models for mutation prediction. (XLSX 9 kb)

Additional file 5: Table S4. Comparison of de novo mutation rates. (XLSX 9 kb)

Additional file 6: Table S5. Joint distribution of common and rare variants for each trio proband. (XLSX 13 kb)

Additional file 7: Table S6. Gene recurrence and burden test. (XLSX 14 kb)

Additional file 8: Table S7. Bioinformatics prediction of the functional impact of DNMs. (XLSX 11 kb)

Additional file 9: Table S8. Characteristics of 116 ENS-related HSCR candidate genes. (XLSX 32 kb)

Additional file 10: Table S9. Sequences and dosages of antisense morpholinos. (XLSX 10 kb)

Additional file 11: Table S10. gRNA and primers for zebrafish knockout and T7E1 assay. (XLSX 9 kb)

Additional file 12: Table S11. Primers for expression analysis in zebrafish. (XLSX 9 kb)

Acknowledgments

The authors would like to thank the patients and families involved in this study. We thank W. W. Pijnappel and M. Broeders for providing the Cas9 protein.

Funding

DS, AB, RC, BE,YS, and RH are supported by research grants from ZonMW (TOP-subsidie 40-00812-98-10042 to BJLE/RMWH) and the Maag Lever Darm stichting (WO09-62 to RMWH); AC is supported by NIH grant R37 HD28088; HG, WC, VL, EN, PS, MS, CT, PT, and MMG-B are supported by Health and Medical Research Fund (HMRF 01121326 to VCHL; HMRF 02131866 to MMGB; and 01121476 to ESWN); General Research Fund (HKU 777612 M to PKT); HKU seed funding for basic research (201110159001 to PKT) and small project funding (201309176158 to CSMT). The work described was also partially supported by a grant from the Research Grant Council of the Hong Kong Special Administrative Region, China, project number T12C-714/14R to PKT; CH and PG are supported by grants from the Italian Ministry of Health through “Cinque per mille” and Ricerca Corrente to the Gaslini Institute; GA, MB, BL-T, MR-F, and SB are supported by the Spanish Ministry of Economy and Competitiveness (Institute of Health Carlos III (ISCIII), PI13/01560 and CDTI, FEDER-Inninterconecta EXP00052887/ITC-20111037), and the Regional Ministry of Innovation, Science and Enterprise of the Autonomous Government of Andalusia (CTS-7447); NINDS (5R21NS082546) awarded to ITS.

Availability of data and materials

We have de-identified all our samples for patient privacy and deposited raw sequence read data in this analysis to the European Nucleotide Archive (with accession number PRJEB19327). The methods and corresponding results generated during this study are included in this published article and its additional files. The primers for zebrafish experiments are all provided in supplementary tables for further replication study in other groups. The identified de novo mutations in four new Hirschsprung genes have been deposited in the NCBI ClinVar database with accession IDs SCV000392345, SCV000494031, SCV000494032, and SCV000494033.

Authors' contributions

HG and DS performed the exome sequencing analyses and wrote the manuscript. WC together with AJB, RC, VL, BJ, TJvH, HCvdL, and ITS performed the zebrafish experiments and prepared the figures for the manuscript. YS and CST conducted the CNV analyses. Sanger sequencing validation was performed by PG, IM, AP, MTS, MRF, BL-T and DS. Statistical support was provided by HG, MB, RWWB, TL, SC, PS, and AC. Expression data were obtained and analyzed by YS and ESWN. Bioinformatics support was provided by SC, JD, PS, MvdH, WvJ, and JBGVM. ASB, CB, PT, JA, SL, RH, BE, MMGB, GA, SB, and IC were involved in patient recruitment and clinical aspects of the study. PT, JA, SL, RH, BE, MMGB, SB, IC, and AC conceived and designed the project. All authors contributed to writing and editing.

Competing interests

The authors declare that they have no competing interests.

Ethics approval

The sequencing study involving Hirschsprung trios was approved by the institutional review board (IRB) of each institution involved. We only used zebrafish embryos till day 5 (dpf 5), which are not considered as animals yet in this study. Hence we don't need to provide IRB approval for our zebrafish experiments as we are free to work with those embryos till 5 dpf.

Author details

¹Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China. ²Centre for Genomic Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China. ³Department of Neuroscience, section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ⁴Department of Clinical Genetics, Erasmus University Medical Center, PO Box 2040300CA Rotterdam, The Netherlands. ⁵Department of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain. ⁶Centre for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain. ⁷McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA. ⁸Department of Medicine, School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ⁹Erasmus Center for Biomics, Erasmus Medical Center, Rotterdam, The Netherlands. ¹⁰Stem Cells and Regenerative Medicine, Birth Defects Research Centre, UCL Institute of Child Health, London, UK. ¹¹UOC Genetica Medica, Istituto Gaslini, Genoa, Italy. ¹²Department of Biology, Emory University, Atlanta, USA. ¹³Laboratory of embryology and genetics of human malformations, INSERM UMR 1163, Institut Imagine, Paris, France. ¹⁴Department of Genetics, Paris Descartes-Sorbonne Paris Cité University, Hôpital Necker-Enfants Malades (APHP), Paris, France. ¹⁵Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. ¹⁶Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Received: 7 October 2016 Accepted: 17 February 2017

Published online: 08 March 2017

References

- Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, Pelet A, Arnold S, Miao X, Griseri P, et al. Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet*. 2008;45:1–14.
- Garcia-Barcelo MM, Tang CS, Ngan ES, Lui VC, Chen Y, So MT, Leon TY, Miao XP, Shum CK, Liu FQ, et al. Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease. *Proc Natl Acad Sci U S A*. 2009;106:2694–9.
- Jiang Q, Arnold S, Heanue T, Kilambi KP, Doan B, Kapoor A, Ling AY, Sosa MX, Guy M, Jiang Q, et al. Functional loss of semaphorin 3C and/or semaphorin 3D and their epistatic interaction with ret are critical to Hirschsprung disease liability. *Am J Hum Genet*. 2015;96:581–96.
- Emison ES, Garcia-Barcelo M, Grice EA, Lantieri F, Amiel J, Burzynski G, Fernandez RM, Hao L, Kashuk C, West K, et al. Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. *Am J Hum Genet*. 2010;87:60–74.
- Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, Gudjonsson SA, Sigurdsson A, Jonasdottir A, Jonasdottir A, et al. Rate of de novo mutations and the importance of father's age to disease risk. *Nature*. 2012;488:471–5.
- Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature*. 2012;485:237–41.
- Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B, Lee YH, Narzisi G, Leotta A, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron*. 2012;74:285–99.
- Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, Gogos JA, Karayiorgou M. Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat Genet*. 2011;43:864–8.
- Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature*. 2014;515:216–21.
- O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature*. 2012;485:246–50.
- Rauch A, Wieczorek D, Graf E, Wieland T, Ende S, Schwarzmayr T, Albrecht B, Bartholdi D, Beygo J, Di Donato N, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet*. 2012;380:1674–82.
- Heanue TA, Pachnis V. Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies. *Nat Rev Neurosci*. 2007;8:466–79.
- Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, Kosmicki JA, Rehnstrom K, Mallick S, Kirby A, et al. A framework for the interpretation of de novo mutation in human disease. *Nat Genet*. 2014;46:944–50.
- Acuna-Hidalgo R, Bo T, Kwint MP, van de Vorst M, Pinelli M, Veltman JA, Hoischen A, Vissers LE, Gilissen C. Post-zygotic point mutations are an underrecognized source of de novo genomic variation. *Am J Hum Genet*. 2015;97:67–74.
- Veltman JA, Brunner HG. De novo mutations in human genetic disease. *Nat Rev Genet*. 2012;13:565–75.
- MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, et al. Guidelines for investigating causality of sequence variants in human disease. *Nature*. 2014;508:469–76.
- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536:285–91.
- Shepherd I, Eisen J. Development of the zebrafish enteric nervous system. *Methods Cell Biol*. 2011;101:143–60.
- Harrison C, Wabbersen T, Shepherd IT. In vivo visualization of the development of the enteric nervous system using a Tg(-8.3bpbox2b:Kaede) transgenic zebrafish. *Genesis*. 2014;52:985–90.
- Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC. p53 activation by knockdown technologies. *PLoS Genet*. 2007;3:e78.
- Jao LE, Wenthe SR, Chen W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. *Proc Natl Acad Sci U S A*. 2013;110:13904–9.
- Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, Lin S, Portnoy ME, Cutler DJ, Green ED, Chakravarti A. A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. *Nature*. 2005;434:857–63.
- Bedell VM, Westcot SE, Ekker SC. Lessons from morpholino-based screening in zebrafish. *Brief Funct Genomics*. 2011;10:181–8.
- Li MX, Kwan JS, Bao SY, Yang W, Ho SL, Song YQ, Sham PC. Predicting mendelian disease-causing non-synonymous single nucleotide variants in exome sequencing studies. *PLoS Genet*. 2013;9:e1003143.

25. Matsui T, Noguchi K, Fukuda M. Dennd3 functions as a guanine nucleotide exchange factor for small GTPase Rab12 in mouse embryonic fibroblasts. *J Biol Chem*. 2014;289:13986–95.
26. Piloto S, Schilling TF. Ovo1 links Wnt signaling with N-cadherin localization during neural crest migration. *Development*. 2010;137:1981–90.
27. Srinivasan S, Anitha M, Mwangi S, Heuckeroth RO. Enteric neuroblasts require the phosphatidylinositol 3-kinase/Akt/Forkhead pathway for GDNF-stimulated survival. *Mol Cell Neurosci*. 2005;29:107–19.
28. Haffner C, Frauli M, Topp S, Irmeler M, Hofmann K, Regula JT, Bally-Cuif L, Haass C. Nicalin and its binding partner Nomo are novel Nodal signaling antagonists. *EMBO J*. 2004;23:3041–50.
29. Schier AF. Nodal signaling in vertebrate development. *Annu Rev Cell Dev Biol*. 2003;19:589–621.
30. Smith JR, Vallier L, Lupo G, Alexander M, Harris WA, Pedersen RA. Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. *Dev Biol*. 2008;313:107–17.
31. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol*. 2009;27:275–80.
32. Fontoura BM, Blobel G, Matunis MJ. A conserved biogenesis pathway for nucleoporins: proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96. *J Cell Biol*. 1999;144:1097–112.
33. Tran EJ, Wentz SR. Dynamic nuclear pore complexes: life on the edge. *Cell*. 2006;125:1041–53.
34. Chakraborty P, Wang Y, Wei JH, van Deursen J, Yu H, Malureanu L, Dasso M, Forbes DJ, Levy DE, Seemann J, Fontoura BM. Nucleoporin levels regulate cell cycle progression and phase-specific gene expression. *Dev Cell*. 2008;15:657–67.
35. Lupu F, Alves A, Anderson K, Doye V, Lacy E. Nuclear pore composition regulates neural stem/progenitor cell differentiation in the mouse embryo. *Dev Cell*. 2008;14:831–42.
36. D'Angelo MA, Gomez-Cavazos JS, Mei A, Lackner DH, Hetzer MW. A change in nuclear pore complex composition regulates cell differentiation. *Dev Cell*. 2012;22:446–58.
37. Liang Y, Franks TM, Marchetto MC, Gage FH, Hetzer MW. Dynamic association of NUP98 with the human genome. *PLoS Genet*. 2013;9:e1003308.
38. Irla M, Puthier D, Granjeaud S, Saade M, Victorero G, Mattei MG, Nguyen C. Genomic organization and the tissue distribution of alternatively spliced isoforms of the mouse *Spatial* gene. *BMC Genomics*. 2004;5:41.
39. Irla M, Saade M, Fernandez C, Chasson L, Victorero G, Dahmane N, Chazal G, Nguyen C. Neuronal distribution of spatial in the developing cerebellum and hippocampus and its somatodendritic association with the kinesin motor KIF17. *Exp Cell Res*. 2007;313:4107–19.
40. Yammine M, Saade M, Chauvet S, Nguyen C. Spatial gene's (Tbata) implication in neurite outgrowth and dendrite patterning in hippocampal neurons. *Mol Cell Neurosci*. 2014;59:1–9.
41. Tang CS, Sribudiani Y, Miao XP, de Vries AR, Burzynski G, So MT, Leon YY, Yip BH, Osinga J, Hui KJ, et al. Fine mapping of the 9q31 Hirschsprung's disease locus. *Hum Genet*. 2010;127:675–83.
42. Pingault V, Guiochon-Mantel A, Bondurand N, Faure C, Lacroix C, Lyonnet S, Goossens M, Landrieu P. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental "neural crest syndrome" related to a SOX10 mutation. *Ann Neurol*. 2000;48:671–6.
43. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. *Biol Psychiatry*. 2006;60:132–40.
44. Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. *J Neurol Neurosurg Psychiatry*. 2003;74:13–9.
45. Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, Witherspoon K, Gerds J, Baker C, Vulto-van Silfhout AT, et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell*. 2014;158:263–76.
46. Van Ginneken C, Schafer KH, Van Dam D, Huygelen V, De Deyn PP. Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. *Brain Res*. 2011;1378:43–53.
47. Wahba G, Schock SC, Claridge E, Bettolli M, Grynspan D, Humphreys P, Staines WA. MeCP2 in the enteric nervous system. *Neurogastroenterol Motil*. 2015;27:1156–61.
48. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25:2078–9.
49. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43:491–8.
50. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010;20:1297–303.
51. Li MX, Gui HS, Kwan JS, Bao SY, Sham PC. A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases. *Nucleic Acids Res*. 2012;40:e53.
52. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38:e164.
53. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559–75.
54. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H. Consortium on the Genetics of S, Group PS, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. *Cell*. 2013;154:518–29.
55. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet*. 2008;83:311–21.
56. Desmet FO, Hamroun D, Lalonde M, Colod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res*. 2009;37:e67.
57. Churkin A, Barash D. RNAmute: RNA secondary structure mutation analysis tool. *BMC Bioinforma*. 2006;7:221.
58. Jiang Q, Ho YY, Hao L, Berrios CN, Chakravarti A. Copy number variants in candidate genes are genetic modifiers of Hirschsprung disease. *Plos One*. 2011;6(6):e21219.
59. Gui HS, Bao JY, Tang CSM, So MT, Ngo DN, Tran AQ, Bui DH, Pham DH, Nguyen TL, Tong A, et al. Targeted next-generation sequencing on Hirschsprung disease: a pilot study exploits DNA pooling. *Ann Hum Genet*. 2014;78:381–7.
60. Alves MM, Sribudiani Y, Brouwer RW, Amiel J, Antinolo G, Borrego S, Ceccherini I, Chakravarti A, Fernandez RM, Garcia-Barcelo MM, et al. Contribution of rare and common variants determine complex diseases-Hirschsprung disease as a model. *Dev Biol*. 2013;382:320–9.
61. Westerfield M. *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, 4th Edition. University of Oregon Press, Eugene; 2000.
62. Moreno-Mateos MA, Vejnar CE, Beaudoin JD, Fernandez JP, Mis EK, Khokha MK, Giraldez AJ. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. *Nat Methods*. 2015;12:982–8.
63. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-ΔΔC_T) method. *Methods*. 2001;25:402–8.
64. Thisse C, Thisse B, Schilling TF, Postlethwait JH. Structure of the zebrafish *Snail1* gene and its expression in wild-type, spadetail and no tail mutant embryos. *Development*. 1993;119:1203–15.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

